Trial Profile
A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Germ cell cancer; Testicular cancer
- Focus Therapeutic Use
- Acronyms RADIT
- 01 Mar 2019 Primary endpoint of progression-free rate at 12 weeks has not been met, according to results published in the Journal of Cancer Research and Clinical Oncology.
- 01 Mar 2019 Results published in the Journal of Cancer Research and Clinical Oncology
- 24 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.